Literature DB >> 11264177

Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia.

A Migliazza1, F Bosch, H Komatsu, E Cayanis, S Martinotti, E Toniato, E Guccione, X Qu, M Chien, V V Murty, G Gaidano, G Inghirami, P Zhang, S Fischer, S M Kalachikov, J Russo, I Edelman, A Efstratiadis, R Dalla-Favera.   

Abstract

Deletions of the 13q14 chromosome region are associated with B-cell chronic lymphocytic leukemia (B-CLL) and several other types of cancer, suggesting the presence of a tumor suppressor gene. In previous studies the minimal region of deletion (MDR) was mapped to a less than 300-kilobase (kb) interval bordered by the markers 173a12-82 and 138G4/1.3R. For the identification of the putative tumor suppressor gene, the entire MDR (approximately 347 kb) has been sequenced, and transcribed regions have been identified by exon trapping, EST-based full-length complementary DNA cloning, database homology searches, and computer-assisted gene prediction analyses. The MDR contains 2 pseudogenes and 3 transcribed genes: CAR, encoding a putative RING-finger containing protein; 1B4/Leu2, generating noncoding transcripts; and EST70/Leu1, probably representing another noncoding gene (longest open reading frame of 78 codons). These genes have been sequenced in 20 B-CLL cases with 13q14 hemizygous deletion, and no mutations were found. Moreover, no somatic variants were found in the entire MDR analyzed for nucleotide substitutions by a combination of direct sequencing and fluorescence-assisted mismatch analysis in 5 B-CLL cases displaying 13q14-monoallelic deletion. The nondeleted allele of the CAR and EST70/Leu1 genes was expressed in B-CLL specimens, including those with monoallelic loss, whereas no expression of 1B4/Leu2 was detectable in B-CLL, regardless of the 13q14 status. These results indicate that allelic loss and mutation of a gene within the MDR is an unlikely pathogenetic mechanism for B-CLL. However, haplo-insufficiency of one of the identified genes may contribute to tumorigenesis. (Blood. 2001;97:2098-2104)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11264177     DOI: 10.1182/blood.v97.7.2098

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

Review 1.  Role of microRNAs in lymphoid biology and disease.

Authors:  Muller Fabbri; Carlo M Croce
Journal:  Curr Opin Hematol       Date:  2011-07       Impact factor: 3.284

Review 2.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

Review 3.  Molecular basis of CLL.

Authors:  Yuri Pekarsky; Nicola Zanesi; Carlo M Croce
Journal:  Semin Cancer Biol       Date:  2010-09-21       Impact factor: 15.707

Review 4.  Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications.

Authors:  George A Calin; Carlo M Croce
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

Review 5.  The molecular pathogenesis of chronic lymphocytic leukaemia.

Authors:  Giulia Fabbri; Riccardo Dalla-Favera
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

6.  Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0 arrays.

Authors:  Jill M Hagenkord; Federico A Monzon; Shera F Kash; Stan Lilleberg; Qingmei Xie; Jeffrey A Kant
Journal:  J Mol Diagn       Date:  2010-01-14       Impact factor: 5.568

7.  The prognostic significance of 13q deletions of different sizes in patients with B-cell chronic lymphoproliferative disorders: a retrospective study.

Authors:  Shuhua Yi; Heng Li; Zengjun Li; Wenjie Xiong; Huimin Liu; Wei Liu; Rui Lv; Zhen Yu; Dehui Zou; Yan Xu; Gang An; Lugui Qiu
Journal:  Int J Hematol       Date:  2017-04-24       Impact factor: 2.490

Review 8.  Global gene expression profiling in the study of multiple myeloma.

Authors:  John D Shaughnessy
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

Review 9.  Coupling transcriptional and post-transcriptional miRNA regulation in the control of cell fate.

Authors:  Reut Shalgi; Ran Brosh; Moshe Oren; Yitzhak Pilpel; Varda Rotter
Journal:  Aging (Albany NY)       Date:  2009-09-08       Impact factor: 5.682

10.  Investigating the targets of MIR-15a and MIR-16-1 in patients with chronic lymphocytic leukemia (CLL).

Authors:  Katy Hanlon; Claudius E Rudin; Lorna W Harries
Journal:  PLoS One       Date:  2009-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.